Lonza Group Ltd. acquired Switzerland-based Micro-Macinazione SA from private equity firm Cross.

Micro-Macinazione provides micronization services for pharmaceutical products and was bought for undisclosed terms. The company had sales of about CHF20 million in 2016.

The deal builds on Lonza's existing micronization capabilities.

Micronization is used in reducing the particle size of active pharmaceutical ingredients so lower doses can be prescribed and side effects can be reduced.

In separate news, Lonza said it priced a loan of €700 million and $200 million to refinance the acquisition of Capsugel S.A.

Commerzbank, Helaba, HSBC, ING Bank and LBBW were the joint arrangers of the loan.